글로벌 마이크로바이옴 조절기 시장 - 2029년까지의 산업 동향 및 예측

글로벌 마이크로바이옴 조절기 시장 분석 및 통찰력

마이크로바이옴은 피부층, 타액 및 위장관(GIT)에 서식하는 미생물 군을 말합니다. 박테리아, 고균 및 균류는 모두 마이크로바이옴 범주에 속합니다. 마이크로바이옴은 인간의 건강에 전반적으로 유익한 특정 작업을 수행하는 데 도움이 됩니다.            

• Data Bridge Market Research는 마이크로바이옴 조절제 시장이 2022년부터 2029년까지의 예측 기간 동안 13.30%의 CAGR로 성장할 것이라고 분석했습니다. 이는 시장 가치가 2021년에 21억 7천만 달러로 평가되었고 2029년까지 58억 9천만 달러로 높아질 것임을 나타냅니다.

마이크로바이옴 조절제 시장 동향

운전자

• 생활 습관 장애

환자의 만성 건강 및 생활 습관 장애의 급증하는 발병률은 효과적인 의료 치료에 대한 수요를 직접적으로 촉진하고 있습니다. 이는 고혈압, 심장마비, 암, 알츠하이머병, 천식, 만성 간 질환, 당뇨병 및 골다공증의 유병률이 증가함에 따라 미생물군 조절제에 대한 수요가 증가할 것임을 나타냅니다.      

• 의료 인프라에 대한 투자 증가

시장 성장률에 영향을 미치는 또 다른 중요한 요인은 의료비 지출 증가로, 이는 인프라 개선에 도움이 됩니다. 특히 개발도상국에서 의료 산업의 성장과 확장은 새롭고 진보된 의료 기술, 장비 및 약물의 사용과 적용을 초대할 것입니다. 이는 마이크로바이옴 조절제 치료에 대한 수요를 직접적으로 증가시킬 것입니다.

• 연구개발 활동

공공 및 민간 시장 참여자 간의 전략적 협업이 증가함에 따라 매일 연구 개발 활동의 수가 증가하고 있습니다. 이러한 연구 개발 능력은 마이크로바이옴 조절제 치료에 대한 수요를 촉진할 신약 및 의료 기술에서 수행되고 있습니다.

또한, 공공 및 민간 기관에서 노인 인구의 증가에 대한 인식을 확산하기 위한 이니셔티브가 증가하고 부작용이 최소인 예방 약물에 대한 수요가 증가하면서 시장 성장률이 확대될 요인이 되었습니다. 효과적인 치료법에 대한 수요 증가, 비용 효율적인 약물의 가용성, 조기 진단 절차에 대한 채택률 증가와 같은 다른 요인은 시장 성장률에 긍정적인 영향을 미칠 것입니다.

기회

Rise in the level of personal disposable income and growing awareness in the developing economies pertaining to the availability of treatment options will further create lucrative market growth opportunities. Rising medical tourism globally, growing number of collaborations between market players, increasing involvement of key players in product development and high potential of growth in the untapped market will create enough market growth opportunities.  

Restraints/Challenges Global Microbiome Modulator Market

However, high costs associated with research and development proficiencies and lack of effective treatment which cut down the scope of innovative medication will emerge as one of the biggest restraints for the market. Dearth of awareness and required infrastructural facilities in the underdeveloped and backward economies, stringent government regulations towards approval of biosimilars and unfavourable conditions arising due to COVID-19 outbreak will further derail the market growth rate. Slow rate of approval for drugs and inhibitors, unmet medical needs and increasing cases of patent expiry will also challenge the market growth rate. 

This microbiome modulator market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on microbiome modulator market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

he Human Microbiome Project, conducted in 2012, reported that more than 10,000 microbial species live in the human ecosystem and comprise trillions of cells, making up 1%-3% of the total body mass.

The microbiome modulator market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Microbiome Modulator Market

This pandemic put a dent on the growth rate of the microbiome modulator market. One of the biggest factors responsible for this is thedecreased funding for research and development activities and overall fall in the number of research and development proficiencies. Also, increased focus on essential activities further derailed the market growth rate.    

Recent Development

• In 2020, Vedanta Biosciences (US) received funding from the Biomedical Advanced Research and Development Authority (BARDA) of USD 7.4 million to advance the clinical development of VE303 for high-risk Clostridioides difficile infection (CDI).

Global Microbiome Modulator Market Scope

The microbiome modulator market is segmented on the basis of products, application, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Products

• Prebiotics
• Creams
• Probiotics
• Drugs
• Others

On the basis of products, the microbiome modulator market is segmented into prebiotics, creams, probiotics, drugs, dietary supplements and others.

Application

• Digestive Health
• Immune Health
• Oral Health
• Others

On the basis of application, microbiome modulator market is segmented into digestive health, immune health, oral health and others.

End-Users

• Hospitals
• Specialty Clinics
• Others

On the basis of end-users, the microbiome modulator market is segmented into hospitals, specialty clinics and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

On the basis of distribution channel, the microbiome modulator market has also been segmented into hospital pharmacy, retail pharmacy and others.

Pipeline Analysis

Microbiome Modulator NM504, developed by MicroBiome Therapeutics LLC, showed promising results in the clinical trial to control blood glucose level and other metabolic parameters in patients with Prediabetes and Type 2 Diabetes.. Quorum Innovations, Merck Sharp & Dohme Corp., Symbiotix Biotherapies, Inc., Ritter Pharmaceuticals and others are the involved in the development of potential drugs for the improvement of treatment of pouchitis treatment.

Microbiome Modulator Market Regional Analysis/Insights

The microbiome modulator market is analysed and market size insights and trends are provided by country, products, application, end-users and distribution channel as referenced above.

The countries covered in the microbiome modulator market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the microbiome modulator market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players, well-developed healthcare infrastructure in this region and increase in the incidence of proctitis and favorable reimbursement policies. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the increase in the awareness about proctitis in developing countries and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Microbiome Modulator Market Share Analysis

The microbiome modulator market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to microbiome modulator market.

Some of the major players operating in the microbiome modulator market are Sanofi, Procter & Gamble, Bayer AG, DSM, DuPont., Yakult Honsha Co., Ltd., BioGaia AB, Probi AB, Chr. Hansen Holding A/S, Ingredion Incorporated, Immuron Ltd, Pharmavite, MICROBIOME THERAPEUTICS, LLC, Otsuka America Pharmaceutical, Inc., Quorum Innovations, Merck Sharp & Dohme Corp., Symbiotix Biotherapies, Inc., and Ritter Pharmaceuticals among others.

Research Methodology : Global Microbiome Modulator Market

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭 다운하세요. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의 사항을 드롭하여 업계 전문가에게 문의하세요  https://www.databridgemarketresearch.com/ko/speak-to-analyst/?dbmr=global-microbiome-modulator-market

SKU-52888